Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001127855-14-000012
Filing Date
2014-01-14
Accepted
2014-01-14 15:31:43
Documents
10
Period of Report
2013-11-30

Document Format Files

Seq Description Document Type Size
1 NAPRODIS 10Q, 11.30.13 naprodis10q113013.htm 10-Q 252192
2 NAPRODIS 10Q, CERTIFICATION 302, CEO naprodisexh31_1.htm EX-31.1 10225
3 NAPRODIS 10Q, CERTIFICATION 302, CFO naprodisexh31_2.htm EX-31.2 10147
4 NAPRODIS 10Q, CERTIFICATION 906, CEO/CFO naprodisexh32.htm EX-32 5993
  Complete submission text file 0001127855-14-000012.txt   1291922

Data Files

Seq Description Document Type Size
5 napr-20131130_cal.xml EX-101.CAL 18510
6 napr-20131130_def.xml EX-101.DEF 7478
7 napr-20131130.xml EX-101.INS 150636
8 napr-20131130_lab.xml EX-101.LAB 65465
9 napr-20131130_pre.xml EX-101.PRE 52851
10 napr-20131130.xsd EX-101.SCH 10032
Mailing Address 13250 GREGG STREET SUITE F POWAY CA 92064
Business Address 13250 GREGG STREET SUITE F POWAY CA 92064 (858) 486-8655
Naprodis, Inc. (Filer) CIK: 0001313938 (see all company filings)

EIN.: 330903494 | State of Incorp.: NV | Fiscal Year End: 0831
Type: 10-Q | Act: 34 | File No.: 333-122009 | Film No.: 14527221
SIC: 2834 Pharmaceutical Preparations